Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Elizabeth A Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Francisco
San Francisco, California, United States
Jo Chien, MDRecruiting - University of Chicago Medical Center
Chicago, Illinois, United States
Withdrawn - University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois, United States
Withdrawn - University of Chicago Medical Center for Advanced Care Orland Park
Orland Park, Illinois, United States
Withdrawn - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Elizabeth A Mittendorf, MD, PHDRecruiting - University of Pennsylvania-Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Angela DeMichele, MDRecruiting - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Vandana Abramson, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Jul 2020
- Primary completion
- 30 Dec 2026
- Completion
- 30 Dec 2027
- Last update posted
- 4 May 2026
- Registered enrollment
- 40
- Registry id
- NCT04434040
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.